Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17126347 | USE OF AN RXR AGONIST IN TREATING HER2+ CANCERS | December 2020 | September 2021 | Allow | 9 | 2 | 0 | No | No |
| 17108728 | Methods for Treating EGFR Mutant Cancers | December 2020 | November 2023 | Abandon | 35 | 1 | 0 | No | No |
| 17097193 | HISTONE DEMETHYLASE INHIBITORS | November 2020 | September 2023 | Allow | 34 | 1 | 0 | No | No |
| 17088466 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | November 2020 | August 2021 | Allow | 10 | 1 | 1 | Yes | No |
| 17052162 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | October 2020 | May 2022 | Allow | 18 | 1 | 0 | No | No |
| 17080425 | AMIDE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS AND METHODS OF TREATMENT | October 2020 | September 2022 | Allow | 23 | 2 | 1 | Yes | No |
| 17050747 | OXO-SUBSTITUTED COMPOUND | October 2020 | January 2023 | Allow | 27 | 1 | 1 | Yes | No |
| 17079152 | INHIBITORS OF RAF KINASES | October 2020 | January 2021 | Allow | 3 | 0 | 1 | No | No |
| 17074002 | USE OF OPIOID ANTAGONISTS | October 2020 | December 2023 | Abandon | 38 | 0 | 1 | No | No |
| 17073615 | SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY | October 2020 | October 2023 | Abandon | 36 | 0 | 1 | No | No |
| 17073253 | LASOFOXIFENE TREATMENT OF BREAST CANCER | October 2020 | December 2023 | Abandon | 38 | 1 | 1 | No | No |
| 17071949 | ACRYLOYL-CONTAINING NUCLEAR TRANSPORT REGULATORS AND USES THEREOF | October 2020 | January 2022 | Allow | 15 | 1 | 0 | Yes | No |
| 17070556 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | October 2020 | July 2023 | Abandon | 33 | 2 | 1 | No | No |
| 17047178 | PROCESS FOR PREPARING MODULATORS OF P300 AND/OR CBP | October 2020 | July 2022 | Allow | 22 | 1 | 0 | No | No |
| 17047002 | QUINAZOLINE COMPOUND SERVING AS EGFR TRIPLE MUTATION INHIBITOR AND APPLICATIONS THEREOF | October 2020 | June 2023 | Allow | 32 | 3 | 1 | No | No |
| 17044007 | Compounds and Their Use as PDE4 Activators | September 2020 | September 2022 | Allow | 23 | 2 | 0 | Yes | No |
| 17043217 | CRYSTALLINE FORMS OF MODULATORS OF CFTR | September 2020 | October 2023 | Abandon | 37 | 1 | 0 | No | No |
| 17042756 | 4-(3-AMINO-6-FLUORO-1H-INDAZOL-5-YL)-1,2,6-TRIMETHYL-1,4-DIHYDROPYRIDINE-3,5-DIC ARBONITRILE COMPOUNDS FOR TREATING HYPERPROLIFERATIVE DISORDERS | September 2020 | July 2022 | Abandon | 21 | 1 | 0 | No | No |
| 17029835 | TARGETED THERAPEUTICS | September 2020 | September 2023 | Abandon | 36 | 0 | 1 | No | No |
| 17023778 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER | September 2020 | May 2023 | Abandon | 32 | 1 | 1 | No | No |
| 17020062 | Analogs of Proxisome Proliferator Activated Receptor (PPAR) Agonists and Methods of Using the Same | September 2020 | October 2022 | Allow | 25 | 2 | 0 | Yes | No |
| 17020555 | IMIDAZOQUINOLINE AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF | September 2020 | January 2021 | Allow | 4 | 1 | 1 | Yes | No |
| 17015319 | COMPOUNDS TARGETING AND DEGRADING BCR-ABL PROTEIN AND ITS ANTITUMOR APPLICATION | September 2020 | November 2022 | Allow | 26 | 1 | 1 | Yes | No |
| 16979457 | TRIAZACYCLODODECANSULFONAMIDE ("TCD")-BASED PROTEIN SECRETION INHIBITORS | September 2020 | February 2022 | Allow | 17 | 1 | 0 | Yes | No |
| 17012788 | TRICYCLIC KINASE INHIBITORS AND USE THEREOF | September 2020 | April 2022 | Abandon | 20 | 1 | 0 | No | No |
| 17001400 | TREATMENT OF SCHIZOPHRENIA | August 2020 | October 2023 | Abandon | 37 | 1 | 1 | No | No |
| 16998731 | COMPOSITIONS AND KITS FOR OMEPRAZOLE SUSPENSION | August 2020 | May 2023 | Allow | 32 | 1 | 0 | Yes | No |
| 16989685 | THERAPIES FOR HEMATOLOGIC MALIGNANCIES | August 2020 | March 2022 | Abandon | 19 | 2 | 0 | No | No |
| 16968429 | ATR INHIBITOR AND APPLICATION THEREOF | August 2020 | April 2022 | Allow | 20 | 1 | 0 | Yes | No |
| 16945039 | NOVEL CONFORMATIONALLY-RESTRICTED ANALOGUES OF SORAFENIB AND REGORAFENIB AS SELECTIVE KINASE INHIBITORS FOR CANCER TREATMENT | July 2020 | March 2022 | Allow | 20 | 1 | 0 | Yes | No |
| 16964274 | Compounds for the Treatment of Kinase-Dependent Disorders | July 2020 | January 2023 | Allow | 29 | 1 | 1 | No | No |
| 16931786 | PYRIDINE AND PYRIMIDINE DERIVATIVES | July 2020 | January 2022 | Allow | 18 | 1 | 0 | No | No |
| 16930581 | Microbicidal Pyrimidine or Triazine Containing Compounds | July 2020 | March 2023 | Abandon | 32 | 3 | 1 | Yes | No |
| 16962724 | Compounds for Treating Rac-GTPase Mediated Disorder | July 2020 | February 2023 | Allow | 31 | 2 | 0 | Yes | No |
| 16928927 | Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress | July 2020 | June 2023 | Allow | 35 | 2 | 1 | Yes | No |
| 16926035 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | July 2020 | September 2022 | Abandon | 27 | 1 | 1 | No | No |
| 16961190 | TETRAHYDROISOQUINOLINE COMPOUNDS | July 2020 | May 2022 | Allow | 23 | 2 | 0 | Yes | No |
| 16924082 | METHODS OF TREATING VIRALLY ASSOCIATED CANCERS WITH HISTONE DEACETYLASE INHIBITORS | July 2020 | February 2021 | Allow | 7 | 1 | 0 | Yes | No |
| 16914703 | FORMULATIONS OF MILCICLIB AND THERAPEUTIC COMBINATIONS OF THE SAME FOR USE IN THE TREATMENT OF CANCER | June 2020 | November 2023 | Abandon | 41 | 3 | 1 | No | No |
| 16958711 | N-ALKYL-N-CYANOALKYLBENZAMIDE COMPOUND AND USE THEREOF | June 2020 | March 2022 | Allow | 20 | 1 | 0 | Yes | No |
| 16909128 | HEST G-18-0 AND BENZOYL PEROXIDE COMPOSITIONS AND METHODS FOR USING THE SAME | June 2020 | April 2022 | Allow | 21 | 2 | 0 | No | No |
| 16955491 | PYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | June 2020 | March 2023 | Abandon | 33 | 0 | 1 | No | No |
| 16903965 | METHODS AND COMPOSITIONS FOR TREATING FATIGUE ASSOCIATED WITH DISORDERED SLEEP USING VERY LOW DOSE CYCLOBENZAPRINE | June 2020 | October 2023 | Abandon | 40 | 3 | 0 | No | No |
| 16954552 | CYCLOHEXYL ACID ISOXAZOLE AZINES AS LPA ANTAGONISTS | June 2020 | December 2021 | Allow | 18 | 1 | 0 | Yes | No |
| 16954501 | PROCESS FOR THE PREPARATION OF OPICAPONE AND INTERMEDIATES THEREOF | June 2020 | December 2022 | Abandon | 30 | 1 | 1 | No | No |
| 16954325 | CYCLOHEXYL ACID PYRAZOLE AZINES AS LPA ANTAGONISTS | June 2020 | December 2021 | Allow | 18 | 1 | 0 | Yes | No |
| 16772842 | CYCLOHEXYL ACID TRIAZOLE AZOLES AS LPA ANTAGONISTS | June 2020 | December 2021 | Allow | 18 | 1 | 0 | Yes | No |
| 16898920 | PHARMACOTHERAPY FOR PREVENTING OR TREATING GLAUCOMA | June 2020 | October 2021 | Abandon | 16 | 1 | 0 | No | No |
| 16897987 | NOVEL INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CANCER CONTAINING THE SAME | June 2020 | March 2022 | Allow | 21 | 1 | 0 | No | No |
| 16898230 | USE OF AN RXR AGONIST IN TREATING HER2+ CANCERS | June 2020 | December 2020 | Allow | 6 | 1 | 0 | Yes | No |
| 16896663 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | June 2020 | February 2023 | Allow | 33 | 2 | 0 | Yes | No |
| 16893750 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | June 2020 | December 2022 | Allow | 30 | 2 | 1 | No | No |
| 16890035 | Prodrug Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | June 2020 | January 2022 | Allow | 20 | 1 | 0 | No | No |
| 16886276 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | May 2020 | June 2022 | Abandon | 24 | 0 | 1 | No | No |
| 16883985 | INHIBITORS OF CAMKK2 AND USES OF SAME | May 2020 | March 2022 | Allow | 22 | 1 | 1 | Yes | No |
| 16881373 | COMPOSITIONS AND METHODS FOR TREATING SEIZURE DISORDERS | May 2020 | August 2022 | Abandon | 27 | 2 | 1 | No | No |
| 16762685 | SELENOPSAMMAPLIN A AND DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR, AND COMPOSITION FOR PREVENTING AND TREATING CANCER, CONTAINING SAME AS ACTIVE INGREDIENTS | May 2020 | January 2023 | Allow | 33 | 2 | 0 | Yes | No |
| 16870572 | Methods for the Administration of Certain VMAT2 Inhibitors | May 2020 | April 2021 | Allow | 11 | 3 | 1 | Yes | No |
| 16870423 | Methods for the Administration of Certain VMAT2 Inhibitors | May 2020 | February 2021 | Allow | 9 | 2 | 1 | No | No |
| 16870823 | Methods for the Administration of Certain VMAT2 Inhibitors | May 2020 | March 2021 | Allow | 10 | 3 | 0 | No | No |
| 16863459 | Continuous Administration of Dopa Decarboxylase Inhibitors and Compositions for Same | April 2020 | November 2022 | Abandon | 31 | 1 | 1 | No | No |
| 16862608 | Solid Forms of a GlyT1 Inhibitor | April 2020 | April 2022 | Allow | 24 | 1 | 1 | No | No |
| 16859413 | PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME | April 2020 | October 2021 | Allow | 18 | 1 | 0 | No | No |
| 16858116 | HETEROCYCLIC INHIBITORS OF TYROSINE KINASE | April 2020 | February 2022 | Allow | 22 | 2 | 0 | Yes | No |
| 16855712 | RET INHIBITOR | April 2020 | December 2022 | Allow | 32 | 2 | 0 | No | No |
| 16855213 | THERAPEUTIC DRUG FOR DYSKINESIA | April 2020 | March 2022 | Abandon | 23 | 1 | 0 | No | No |
| 16851648 | FUROSTAN-3-OL DERIVATIVES AS SKELETAL MUSCLE HYPERTROPHIC AGENTS | April 2020 | August 2021 | Allow | 16 | 1 | 0 | No | No |
| 16754821 | METHOD FOR PREPARING 3-[(4S)-8-BROMO-1-METHYL-6-(PYRIDIN-2-YL)-4H-IMIDAZO[1,2-A][1,4]BENZODIAZEPIN-4-YL]-PROPIONIC ACID METHYL ESTER, AND COMPOUNDS USEFUL IN SAID METHOD | April 2020 | February 2022 | Allow | 22 | 1 | 1 | No | No |
| 16652780 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS AND METHODS OF USING THE SAME | April 2020 | February 2022 | Abandon | 23 | 1 | 0 | No | No |
| 16835719 | PHARMACEUTICAL COMPOSITION FOR TREATING TUMOR | March 2020 | January 2021 | Allow | 10 | 1 | 0 | Yes | No |
| 16834543 | METHODS OF TREATING AGE-RELATED SYMPTOMS IN MAMMALS AND COMPOSITIONS THEREFOR | March 2020 | August 2022 | Abandon | 29 | 2 | 0 | No | No |
| 16829597 | 1,2,3-TRIAZOLE DERIVATIVES AND USES THEREOF | March 2020 | December 2021 | Abandon | 21 | 1 | 0 | No | No |
| 16649717 | CRBN LIGANDS AND USES THEREOF | March 2020 | February 2022 | Allow | 23 | 1 | 1 | Yes | No |
| 16824885 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | March 2020 | October 2021 | Allow | 19 | 1 | 0 | No | No |
| 16824443 | TARGETING GLIOBLASTOMA STEM CELLS THROUGH THE TLX-TET3 AXIS | March 2020 | July 2022 | Abandon | 28 | 1 | 1 | No | No |
| 16648737 | COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 | March 2020 | October 2022 | Allow | 30 | 1 | 1 | Yes | No |
| 16821098 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | March 2020 | March 2022 | Allow | 24 | 1 | 1 | Yes | No |
| 16816132 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | March 2020 | August 2022 | Allow | 29 | 2 | 1 | No | No |
| 16799956 | COMPOSITION FOR TREATING OCULAR DISORDERS SUCH AS MACULAR DEGENERATION, RETINOPATHY AND GLAUCOMA | February 2020 | December 2021 | Abandon | 22 | 1 | 0 | No | No |
| 16797081 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | February 2020 | March 2023 | Abandon | 37 | 2 | 1 | No | No |
| 16639964 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) FLT3 INHIBITORS | February 2020 | March 2022 | Allow | 24 | 2 | 0 | Yes | No |
| 16639646 | Chemical Compound, Pharmaceutical Composition Thereof, and Use and Application Thereof | February 2020 | December 2021 | Abandon | 22 | 1 | 0 | No | No |
| 16790197 | Pharmaceutical Compositions and Their Use for Treatment of Cancer and Autoimmune Diseases | February 2020 | February 2022 | Allow | 24 | 1 | 1 | No | No |
| 16789724 | DERMATOLOGICAL COMPOSITIONS AND METHODS | February 2020 | November 2020 | Abandon | 9 | 1 | 0 | No | No |
| 16781964 | TREATMENT OF CANCER WITH SPECIFIC RXR AGONISTS | February 2020 | December 2020 | Allow | 11 | 2 | 0 | Yes | No |
| 16776984 | DICLOFENAC AND HYALURONIC ACID COMBINATION TREATMENT FOR ORAL LEUKPOPLAKIA | January 2020 | January 2023 | Allow | 36 | 2 | 1 | Yes | No |
| 16776190 | METHOD OF INCREASING MELATONIN SYNTHESIS TO TREAT INSOMNIA, AMELIORATE SLEEP DISTURBANCE AND REGULATE SLEEP | January 2020 | December 2020 | Allow | 10 | 2 | 0 | Yes | No |
| 16739948 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RETINOPATHY AND OTHER OCULAR DISEASES | January 2020 | September 2022 | Allow | 33 | 2 | 1 | No | No |
| 16739873 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RETINOPATHY AND OTHER OCULAR DISEASES | January 2020 | September 2022 | Allow | 33 | 2 | 1 | No | No |
| 16738103 | COMBINATION THERAPY WITH AXL INHIBITOR AND IMMUNE CHECKPOINT MODULATOR OR ONCOLYTIC VIRUS | January 2020 | February 2022 | Allow | 25 | 1 | 1 | Yes | No |
| 16736705 | TREATMENT OF DISEASES BY CONCURRENTLY ELICITING REMYELINATION EFFECTS AND IMMUNOMODULATORY EFFECTS USING SELECTIVE RXR AGONISTS | January 2020 | September 2022 | Abandon | 33 | 1 | 1 | No | No |
| 16728566 | APILIMOD COMPOSITIONS AND METHODS FOR USING SAME | December 2019 | October 2021 | Allow | 22 | 1 | 0 | No | No |
| 16703180 | Cyclopenta[d]pyrimidines And Substituted Cyclopenta[d]pyrimidines As Antitubulin and Microtubule Targeting Agents, Monocyclic Pyrimidines As Tubulin Inhibitors, And Pyrrolopyrimidines As Targeted Antifolates And Tubulin and Multiple Receptor Tyrosine Kinase Inhibition And Antitumor Agents | December 2019 | May 2021 | Allow | 17 | 1 | 0 | No | No |
| 16700522 | TRICYCLIC SPIRO COMPOUND | December 2019 | August 2021 | Allow | 20 | 1 | 1 | Yes | No |
| 16697611 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RETINOPATHY AND OTHER OCULAR DISEASES | November 2019 | May 2022 | Allow | 30 | 2 | 1 | No | No |
| 16695814 | APILIMOD COMPOSITIONS AND METHODS FOR USING SAME IN THE TREATMENT OF RENAL CANCER | November 2019 | May 2021 | Allow | 18 | 1 | 0 | No | No |
| 16617471 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | November 2019 | March 2023 | Allow | 39 | 4 | 1 | Yes | No |
| 16689965 | COMBINATION THERAPY FOR HEAD AND NECK CANCER | November 2019 | December 2023 | Abandon | 49 | 4 | 1 | No | No |
| 16678988 | METHODS FOR SHRINKING PITUITARY TUMORS | November 2019 | February 2021 | Allow | 57 | 2 | 0 | No | No |
| 16675669 | PHARMACEUTICALLY ACCEPTABLE SALTS OF BETA-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF | November 2019 | April 2022 | Abandon | 29 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner JEAN-LOUIS, SAMIRA JM.
With a 30.8% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 18.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner JEAN-LOUIS, SAMIRA JM works in Art Unit 1627 and has examined 980 patent applications in our dataset. With an allowance rate of 51.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.
Examiner JEAN-LOUIS, SAMIRA JM's allowance rate of 51.9% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by JEAN-LOUIS, SAMIRA JM receive 1.73 office actions before reaching final disposition. This places the examiner in the 34% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by JEAN-LOUIS, SAMIRA JM is 30 months. This places the examiner in the 58% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +55.8% benefit to allowance rate for applications examined by JEAN-LOUIS, SAMIRA JM. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 24.1% of applications are subsequently allowed. This success rate is in the 38% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 49.2% of cases where such amendments are filed. This entry rate is in the 74% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 43% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 75.9% of appeals filed. This is in the 67% percentile among all examiners. Of these withdrawals, 61.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 71.3% are granted (fully or in part). This grant rate is in the 77% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 1.0% of allowed cases (in the 67% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 8.3% of allowed cases (in the 88% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.